Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01470118 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 127
- Enrollment target
NCT01470118: Completed Phase 4 study, sponsored by Allergan.
NCT01470118 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 127 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01470118, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 127 participants
- Enrollment target
Study Summary
This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.
Primary Outcome
Ocular itching evaluated by the subject at 3, 5, and 7 minutes post challenge on Day 0 (Visit 3) at hour 16. Subjects scored their ocular itching on a numeric analog scale ranging from 0=None to 4=Incapacitating Itch with an Irresistible Urge to Rub (0.5 increments were allowed). For each subject, the score for both eyes was averaged (i.e., one score per subject). A lower score was indicative of less itching.
Interventions
- DRUG dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
- DRUG alcaftadine 0.25% ophthalmic solution
- DRUG olopatadine 0.2% ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2011-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
What the finished NCT01470118 record still lists
NCT01470118 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 3 interventions - of which dextran 70 0.1%/hydroxypropyl methylcellulose 0.3% is the first listed.
NCT01470118 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01470118 about?
NCT01470118 is a clinical study titled "A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis". This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.
What is the current status of trial NCT01470118?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 127 participants. The study started on 2011-10. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01470118?
The interventions under investigation include: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3% (DRUG), alcaftadine 0.25% ophthalmic solution (DRUG), olopatadine 0.2% ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT01470118?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01470118's enrollment target sits among peer trials
127 639th of 2000 higher than 1,355 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03017820 · 127 participants · Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- NCT03609580 · 127 participants · Phase 1
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
- NCT06285643 · 127 participants · Phase 2
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- NCT06809400 · 127 participants · Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia